首页> 美国卫生研究院文献>Oncology Letters >CD14+HLA-DRlow/− expression: A novel prognostic factor in chronic lymphocytic leukemia
【2h】

CD14+HLA-DRlow/− expression: A novel prognostic factor in chronic lymphocytic leukemia

机译:CD14 + HLA-DRlow /-表达:慢性淋巴细胞性白血病的新预后因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Currently, no prognostic factors exist for determining the host immune status of chronic lymphocytic leukemia (CLL) patients. Therefore, the present report analyzed cluster of differentiation 14 (CD14)+ human leukocyte antigen (HLA)-DRlow/− myeloid-derived suppressor cells (MDSC) from 49 CLL patients and demonstrated that these cells were significantly expanded in all CLL patients when compared with monoclonal B cell lymphocytosis patients and healthy volunteers. Furthermore, upregulation of CD14+HLA-DRlow/− MDSCs was correlated with CLL tumor progression and a poor prognosis for CLL patients, and CD14+HLA-DRlow/− MDSCs were significantly correlated with the presence of CD4+ T and CD5+CD19+ cells in CLL patients, which could significantly inhibit the CD4+ T-cell immune response, contributing to CLL cell progression in CLL patients.
机译:目前,尚无确定慢性淋巴细胞性白血病(CLL)患者宿主免疫状态的预后因素。因此,本报告分析了49个CLL分化的14(CD14)+ sup>人白细胞抗原(HLA)-DR low /-髓样来源的抑制细胞(MDSC)的簇并证明,与单克隆B细胞淋巴细胞增多症患者和健康志愿者相比,这些细胞在所有CLL患者中均显着扩增。此外,CD14 + HLA-DR low /- MDSCs的上调与CLL肿瘤进展和CLL患者预后差有关,而CD14 + HLA-DR low /- MDSC与CD4 + T和CD5 + CD19 + 细胞,可显着抑制CD4 + T细胞免疫反应,促进CLL患者的CLL细胞进程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号